Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Jan A. Burger, Tadeusz Robak, Fatih Demırkan, Osnat Bairey, Carol Moreno, David Simpson, Talha Munir, Don A. Stevens, Sandra Dai, Leo W.K. Cheung, Kevin Kwei, Indu Lal, Emily Hsu, Thomas J. Kipps, Alessandra Tedeschi
Abstract
mutated 1.05 (0.65-1.69). This integrated analysis demonstrated efficacy of first-line ibrutinib-based treatment irrespective of cytogenetic and mutational risk features.Registered at ClinicalTrials.gov (NCT01722487 and NCT02264574).
Topics & Concepts
IbrutinibIGHV@Chronic lymphocytic leukemiaChlorambucilOncologyInternal medicineHazard ratioVenetoclaxChemoimmunotherapyMedicineProgression-free survivalLeukemiaChemotherapyConfidence intervalCyclophosphamideChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders